Skip to main content
Breakthrough Therapy status granted to Janssen vaccine candidate
9/9/2019

The FDA granted Breakthrough Therapy designation to Janssen's investigational prophylactic vaccine as a preventive treatment for respiratory syncytial virus-mediated lower respiratory tract disease for adult patients 60 years old and older.

Full Story: